Accordingly, our recent study found that treatment with recombinant Erdr1 suppressed the expression of VEGF and reduced the angiogenesis in a murine rosacea model, implying its therapeutic possibilities for human patients with rosacea [102]. Here, VEGFA is linked to rosacea.